Your browser doesn't support javascript.
loading
Cholangiocarcinoma, 10-Year Survival After Liver Transplantation: A Case Report.
Herrero Torres, Maria Angeles; Dominguez Bastante, Mireia; Molina Raya, Andrea; Palomo Lopez, Irina; Santoyo Villalba, Julio; Villegas Herrera, Maria Trinidad; Becerra Massare, Antonio; Brea Gomez, Esther; Zambudio Carroll, Natalia; Villar Del Moral, Jesus Maria.
Afiliación
  • Herrero Torres MA; Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain. Electronic address: mherrerot@hotmail.com.
  • Dominguez Bastante M; Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Molina Raya A; Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Palomo Lopez I; Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Santoyo Villalba J; Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Villegas Herrera MT; Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Becerra Massare A; Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Brea Gomez E; Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Zambudio Carroll N; Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Villar Del Moral JM; Department of HBP Surgery and Transplantation, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Transplant Proc ; 52(2): 592-593, 2020 Mar.
Article en En | MEDLINE | ID: mdl-32057500
ABSTRACT
Cholangiocarcinoma is the second most common neoplasm in the liver, with a very poor, short-term prognosis. Today, surgery associated with or without an adjuvant is the only curative treatment. Liver transplantation (LT) is the best treatment for hepatocellular carcinoma tumor. In recent years, treatment of hilar cholangiocarcinoma by LT associated with neoadjuvant therapy has been studied under a criterion. But could it be possible to apply LT like the curative treatment of intrahepatic cholangiocarcinoma (iCC)? Initially the answer is no, but there are different studies about incidental LT in patients with iCC that demonstrate survival over 40% to 50%. In our center, we conducted a review of 468 transplants completed between 2002 and 2018, and we identified 1 case of incidental LT in a patient with iCC with an overall survival of 10 years. Because there is currently an increase in donors owing to the expansion of the criteria, a study to consider extending the criteria of LT to include iCC would be beneficial.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Trasplante de Hígado / Colangiocarcinoma Tipo de estudio: Observational_studies / Prognostic_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Transplant Proc Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Trasplante de Hígado / Colangiocarcinoma Tipo de estudio: Observational_studies / Prognostic_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Transplant Proc Año: 2020 Tipo del documento: Article